<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01165177</url>
  </required_header>
  <id_info>
    <org_study_id>110390</org_study_id>
    <secondary_id>2008-000367-42</secondary_id>
    <nct_id>NCT01165177</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older</brief_title>
  <official_title>Efficacy, Safety, and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 50 Years or Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this observer-blind study is to evaluate the efficacy, safety and
      immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in adults aged ≥ 50
      years.

      Two studies [ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229)] are being conducted
      concurrently to evaluate efficacy of GSK1437173A vaccine. A pooled analysis of data from both
      studies combined will be conducted contingent on each study achieving its objectives. The
      protocol posting of study ZOSTER-022 also deals with the outcome measures related to the
      pooled analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol summary has been updated following Protocol Amendment 4 changes to study
      objectives and endpoints and the analyses of the objectives in 2 steps.

      Step 1 will include analyses of the following objectives of ZOSTER-006 (NCT01165177): all HZ
      VE objectives and all reactogenicity/safety and immunogenicity objectives. At step 2, all
      objectives of study ZOSTER-006 (NCT01165177) will be analyzed. Objectives already analyzed at
      step 1 will be re-analyzed (confirmatory descriptive in case of inferential analysis at step
      1 or descriptive analysis otherwise). At step 2, pooled analyses of studies ZOSTER-006
      (NCT01165177) and ZOSTER-022 (NCT01165229) are planned; overall PHN VE in subjects ≥ 70 YOA,
      and other pre-specified endpoints will be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1, 2010</start_date>
  <completion_date type="Actual">July 27, 2015</completion_date>
  <primary_completion_date type="Actual">May 9, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Confirmed Herpes Zoster (HZ) Cases</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>Confirmed HZ cases during the study were assessed in the Modified Total Vaccinated Cohort (mTVc)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Episodes of Post-Herpetic Neuralgia (PHN)</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>The incidence of PHN was calculated using the modified total vaccinated chort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a Reduction of Duration of Severe 'Worst' HZ-associated Pain</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>Severe 'worst' pain was defined as HZ-associated pain rated as 3 or above on the 'worst pain' Zoster Brief Pain Inventory (ZBPI) questionnaire. The outcome assessed the duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period as measured by the ZBPI in subjects with confirmed HZ. This analysis involved any subject reporting clinically significant pain (i.e. pain with a score of 3 or more on a 0-10 point scale) at any time during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Confirmed HZ Episode Related Mortality</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>The analysis focused on the number of subjects who died due to HZ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With HZ Related Complications</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>The analysis focused on the incidence of HZ complications in subjects with confirmed HZ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Confirmed HZ Episode Related Hospitalizations</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>The analysis focused on confirmed HZ episode related hospitalizations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a Confirmed HZ Episode Having a Reduction of Duration of Pain Medication Associated With HZ</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>The analysis focused on patients who experienced a reduction in duration of pain medication administered for HZ in subjects with confirmed HZ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a Confirmed HZ Episode Taking Pain Medication Associated With HZ</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>The analysis focused on subjects taking pain medication due to HZ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Severe 'Worst' HZ-associated Pain.</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>Severe 'worst' pain was defined as HZ-associated pain rated as 3 or above on the 'worst pain' ZBPI questionnaire. This Outcome Measure was only assessed participants with confirmed HZ. This analysis involved any subject reporting ZBPI clinically significant pain (i.e. pain with a score of 3 or more on a 0-10 point scale) at any time during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Confirmed HZ Episode Related Mortality and Hospitalizations</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>The analysis focused on confirmed HZ episode related hospitalizations and deaths.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With HZ Related Complications, by Complication Type</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>Complication types included HZ vasculitis, Disseminated Disease, Ophtalmic Disease, Neurologic Disease, Visceral Disease and Stroke. This Outcome Measure was only assessed participants with confirmed HZ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Pain Medication Associated With HZ</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>The distribution of pain medication included 1 to 3 or more separate medications. This Outcome Measure was only assessed participants with confirmed HZ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Pain Medication Associated With HZ</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>The analysis was performed in subjects with a confirmed HZ episode</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</measure>
    <time_frame>During the 7-day (Days 0-6) post-vaccination period</time_frame>
    <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>Within the 7-day (Days 0-6) post-vaccination period</time_frame>
    <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, fever [defined as oral, axillary, rectal or tympanic temperature equal to or above 37.5 degrees Celsius (°C)], headache, myalgia, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Grade 3 Symptoms (Solicited and Unsolicited)</measure>
    <time_frame>Within the 7-day (Days 0-6) post-vaccination period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>Occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs) in all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With AEs With Any and Related Medically Attended Visit (MAEs)</measure>
    <time_frame>From Month 0 to Month 8 post-vaccination</time_frame>
    <description>Occurrence and relationship to vaccination of medically attended visits (defined as hospitalizations, emergency room visits or visits to or from medical personnel), other than routine health care visits in all subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Within 30 days (Days 0 - 29) after each vaccination</time_frame>
    <description>Occurrence, intensity and relationship to vaccination of unsolicited AEs, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>Within the 30-day (Days 0-29) post-vaccination period, up to Month 14 and up to study end (3 to 5 year period following Day 0)</time_frame>
    <description>Occurrence and relationship to vaccination of all SAEs in all subjects. Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16165</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>Zoster vaccine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive NaCl solution placebo according to a 0, 2-month schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Herpes Zoster Vaccine GSK1437173A</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Zoster vaccine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes will comply with the requirements of the
             protocol;

          -  Written informed consent obtained from the subject;

          -  A male or female aged 50 years or older at the time of the first vaccination;

          -  Female subjects of non-childbearing potential may be enrolled in the study;

        For this study population, non-childbearing potential is defined as current tubal ligation,
        hysterectomy, ovariectomy or post-menopause.

        OR Female subjects of childbearing potential may be enrolled in the study, if the subject
        has practiced adequate contraception for 30 days prior to vaccination, and has a negative
        urine pregnancy test on the day of vaccination, and has agreed to continue adequate
        contraception during the entire treatment period and for 2 months after completion of the
        vaccination series;

        Exclusion Criteria:

          -  Use of any investigational or non-registered product other than the study vaccine
             within 30 days preceding the first dose of study vaccine, or planned use during the
             study period;

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product;

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition resulting
             from disease or immunosuppressive/cytotoxic therapy;

          -  History of HZ;

          -  Previous vaccination against varicella or HZ;

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine. Additionally, consider allergic reactions to other material or equipment
             related to study participation;

          -  Significant underlying illness that in the opinion of the investigator would be
             expected to prevent completion of the study;

          -  Receipt of immunoglobulins and/or any blood products within the 90 days preceding the
             first dose of study vaccine or planned administration during the study period;

          -  Administration or planned administration of any other immunizations within 30 days
             before the first or second study vaccination or scheduled within 30 days after study
             vaccination. However, licensed non-replicating vaccines may be administered up to 8
             days prior to each dose and/or at least 14 days after any dose of study vaccine;

          -  Any other condition that, in the opinion of the investigator, might interfere with the
             evaluations required by the study;

          -  Acute disease and/or fever at the time of enrollment;

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first vaccine dose.

          -  Pregnant or lactating female;

          -  Female planning to become pregnant or planning to discontinue contraceptive
             precautions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wadsworth</city>
        <state>Ohio</state>
        <zip>44281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carnegie</city>
        <state>Pennsylvania</state>
        <zip>15106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pleasant Hills</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glebe</city>
        <state>New South Wales</state>
        <zip>2037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maroubra</city>
        <state>New South Wales</state>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Umina</city>
        <state>New South Wales</state>
        <zip>2257</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2522</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherwood</city>
        <state>Queensland</state>
        <zip>4075</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ivanhoe</city>
        <state>Victoria</state>
        <zip>3079</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Curitiba/Paraná</city>
        <state>Paraná</state>
        <zip>80810-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Curitiba/PR</city>
        <zip>80240-280</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>04038 002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>04266-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>04312903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bay Roberts</city>
        <state>Newfoundland and Labrador</state>
        <zip>A0A 1G0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4S 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Woodstock</city>
        <state>Ontario</state>
        <zip>N4S 5P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y 6S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1E 7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 2G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trois Rivières</city>
        <state>Quebec</state>
        <zip>G8T 7A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>662 10</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 04</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>13619</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tartu</city>
        <zip>50106</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Espoo</city>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jarvenpaa</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seinajoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cherbourg</city>
        <zip>50100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Château Gontier</city>
        <zip>53200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Laval</city>
        <zip>53000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Laval</city>
        <zip>53100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montrevault</city>
        <zip>49110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muret</city>
        <zip>31600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nantes</city>
        <zip>44300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosiers d'Egletons</city>
        <zip>19300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Cyr Sur Loir</city>
        <zip>37540</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Segré</city>
        <zip>49500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Soulaines sur Aubance</city>
        <zip>49610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tours</city>
        <zip>37100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Deggingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>73326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gueglingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>74363</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wangen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>88239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weinheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dachau</city>
        <state>Bayern</state>
        <zip>85221</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kuenzing</city>
        <state>Bayern</state>
        <zip>94550</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80339</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rednitzhembach</city>
        <state>Bayern</state>
        <zip>91126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wallerfing</city>
        <state>Bayern</state>
        <zip>94574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Potsdam</city>
        <state>Brandenburg</state>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Floersheim</city>
        <state>Hessen</state>
        <zip>65439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duelmen</city>
        <state>Niedersachsen</state>
        <zip>48249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goch</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Witten</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58455</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rhaunen</city>
        <state>Rheinland-Pfalz</state>
        <zip>55624</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koethen</city>
        <state>Sachsen-Anhalt</state>
        <zip>06366</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freiberg</city>
        <state>Sachsen</state>
        <zip>09599</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04315</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pirna</city>
        <state>Sachsen</state>
        <zip>01796</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23554</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kwun Tong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chieti</city>
        <state>Abruzzo</state>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pescara</city>
        <state>Abruzzo</state>
        <zip>65100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monza</city>
        <state>Lombardia</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cuneo</city>
        <state>Piemonte</state>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sassari</city>
        <state>Sardegna</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ragusa (RG)</city>
        <state>Sicilia</state>
        <zip>97100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>813-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>816-0864</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>224-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyoto</city>
        <zip>611-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>141-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>154-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ansan</city>
        <zip>425-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucheon-si,</city>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kangnam-gu, Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kangwon-do</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>150-950</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zapopan, Jalisco</city>
        <state>Jalisco</state>
        <zip>45190</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <zip>62210</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durango</city>
        <zip>34000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alcover( Tarragona)</city>
        <zip>43460</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Balenyà (Barcelona)</city>
        <zip>08550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Centelles</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Roca Del Valles (Barcelona)</city>
        <zip>08430</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Majadahonda</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Peralada( Girona)</city>
        <zip>17491</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46020</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vic/ Barcelona</city>
        <zip>08500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Borås</city>
        <zip>SE-506 30</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eskilstuna</city>
        <zip>SE-631 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jönköping</city>
        <zip>SE-551 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Karlskrona</city>
        <zip>SE-371 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Linköping</city>
        <zip>SE-58758</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malmö</city>
        <zip>SE-211 52</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Skövde</city>
        <zip>SE-541 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-111 57</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vällingby</city>
        <zip>SE-162 68</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Örebro</city>
        <zip>SE-703 62</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buckshaw Village, Chorley</city>
        <state>Lancashire</state>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atherstone</city>
        <state>Warwickshire</state>
        <zip>CV9 1EU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bradford on Avon</city>
        <state>Wiltshire</state>
        <zip>BA15 1DQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangor</city>
        <zip>BT19 1PP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT7 2EB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Broughshane</city>
        <zip>BT42 4JP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ledbury</city>
        <zip>HR8 2AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newtonabbey</city>
        <zip>BT37 9QW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waterloo, Liverpool</city>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2010</study_first_submitted>
  <study_first_submitted_qc>July 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2010</study_first_posted>
  <results_first_submitted>July 28, 2016</results_first_submitted>
  <results_first_submitted_qc>March 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2017</results_first_posted>
  <disposition_first_submitted>August 22, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>August 22, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 30, 2013</disposition_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>subjects 50 years and older</keyword>
  <keyword>vaccine</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>efficacy</keyword>
  <keyword>Herpes Zoster</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Out of all the subjects enrolled into this study, only 15405 received vaccination and were hence considered to start the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK1437173A Group</title>
          <description>Subjects received herpes zoster subunit vaccine (gE/AS01B vaccine: GSK1437173A) according to a 0, 2-month schedule.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Subjects received saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7695"/>
                <participants group_id="P2" count="7710"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6773"/>
                <participants group_id="P2" count="6808"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="922"/>
                <participants group_id="P2" count="902"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="372"/>
                <participants group_id="P2" count="356"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serious Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="229"/>
                <participants group_id="P2" count="240"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="195"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site closure</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject non-compliant with procedures</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Previous health issues worsening</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject missed visit</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Migrated/moved from study area</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-serious Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal Reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK1437173A Group</title>
          <description>Subjects received herpes zoster subunit vaccine (gE/AS01B vaccine: GSK1437173A) according to a 0, 2-month schedule.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Subjects received saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7695"/>
            <count group_id="B2" value="7710"/>
            <count group_id="B3" value="15405"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" spread="9.0"/>
                    <measurement group_id="B2" value="62.3" spread="9.0"/>
                    <measurement group_id="B3" value="62.35" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>50 - 59 YOA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3644"/>
                    <measurement group_id="B2" value="3642"/>
                    <measurement group_id="B3" value="7286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 - 69 YOA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2243"/>
                    <measurement group_id="B2" value="2245"/>
                    <measurement group_id="B3" value="4488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 70 YOA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1808"/>
                    <measurement group_id="B2" value="1823"/>
                    <measurement group_id="B3" value="3631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4709"/>
                    <measurement group_id="B2" value="4711"/>
                    <measurement group_id="B3" value="9420"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2986"/>
                    <measurement group_id="B2" value="2999"/>
                    <measurement group_id="B3" value="5985"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Confirmed Herpes Zoster (HZ) Cases</title>
        <description>Confirmed HZ cases during the study were assessed in the Modified Total Vaccinated Cohort (mTVc)</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>GSK1437173A 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>GSK1437173A Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>GSK1437173A Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Placebo 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Placebo 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Confirmed Herpes Zoster (HZ) Cases</title>
          <description>Confirmed HZ cases during the study were assessed in the Modified Total Vaccinated Cohort (mTVc)</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3492"/>
                <count group_id="O2" value="2141"/>
                <count group_id="O3" value="1711"/>
                <count group_id="O4" value="7344"/>
                <count group_id="O5" value="3525"/>
                <count group_id="O6" value="2166"/>
                <count group_id="O7" value="1724"/>
                <count group_id="O8" value="7415"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="87"/>
                    <measurement group_id="O6" value="75"/>
                    <measurement group_id="O7" value="48"/>
                    <measurement group_id="O8" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criteria for the vaccine efficacy (VE) objective of herpes zoster subunit (HZ/su) vaccine against herpes zoster (HZ) vaccine, in the 50-59 YOA age strata : The lower limit (LL) of the two-sided 95% confidence interval (CI) of VE had to be above 10%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Poisson</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>96.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.6</ci_lower_limit>
            <ci_upper_limit>99.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criteria for the vaccine efficacy (VE) objective of herpes zoster subunit (HZ/su) vaccine against herpes zoster (HZ) vaccine, in the 60-69 YOA age strata : The lower limit (LL) of the two-sided 95% confidence interval (CI) of VE had to be above 10%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Poisson</method>
            <param_type>1-Risk Ratio</param_type>
            <param_value>97.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>90.1</ci_lower_limit>
            <ci_upper_limit>99.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criteria for the vaccine efficacy (VE) objective of herpes zoster subunit (HZ/su) vaccine against herpes zoster (HZ) vaccine, in the 70-79 YOA age strata : The lower limit (LL) of the two-sided 95% confidence interval (CI) of VE had to be above 10%.</non_inferiority_desc>
            <p_value>0.0001</p_value>
            <method>Poisson</method>
            <param_type>1-Risk Ratio</param_type>
            <param_value>97.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>87.9</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criteria for the vaccine efficacy (VE) objective of herpes zoster subunit (HZ/su) vaccine against herpes zoster (HZ) vaccine, in the overall age strata : The lower limit (LL) of the two-sided 95% confidence interval (CI) of VE had to be above 10%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Poisson</method>
            <param_type>1-Risk Ratio</param_type>
            <param_value>97.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.7</ci_lower_limit>
            <ci_upper_limit>99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Episodes of Post-Herpetic Neuralgia (PHN)</title>
        <description>The incidence of PHN was calculated using the modified total vaccinated chort.</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>GSK1437173A 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>GSK1437173A Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>GSK1437173A Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Placebo 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Placebo 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Episodes of Post-Herpetic Neuralgia (PHN)</title>
          <description>The incidence of PHN was calculated using the modified total vaccinated chort.</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3491"/>
                <count group_id="O2" value="2140"/>
                <count group_id="O3" value="1709"/>
                <count group_id="O4" value="7430"/>
                <count group_id="O5" value="3523"/>
                <count group_id="O6" value="2166"/>
                <count group_id="O7" value="1724"/>
                <count group_id="O8" value="7413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0081</p_value>
            <method>Poisson Method</method>
            <param_type>1-RR</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>40.9</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5097</p_value>
            <method>Poisson Method</method>
            <param_type>1-RR</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-442.8</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0078</p_value>
            <method>Poisson Method</method>
            <param_type>1-RR</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>41.4</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Poisson Method</method>
            <param_type>1-RR</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>77.1</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a Reduction of Duration of Severe ‘Worst’ HZ-associated Pain</title>
        <description>Severe 'worst' pain was defined as HZ-associated pain rated as 3 or above on the 'worst pain' Zoster Brief Pain Inventory (ZBPI) questionnaire. The outcome assessed the duration of severe ‘worst’ HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period as measured by the ZBPI in subjects with confirmed HZ. This analysis involved any subject reporting clinically significant pain (i.e. pain with a score of 3 or more on a 0-10 point scale) at any time during the study.</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>GSK1437173A 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>GSK1437173A Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>GSK1437173A Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Placebo 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Placebo 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Reduction of Duration of Severe ‘Worst’ HZ-associated Pain</title>
          <description>Severe 'worst' pain was defined as HZ-associated pain rated as 3 or above on the 'worst pain' Zoster Brief Pain Inventory (ZBPI) questionnaire. The outcome assessed the duration of severe ‘worst’ HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period as measured by the ZBPI in subjects with confirmed HZ. This analysis involved any subject reporting clinically significant pain (i.e. pain with a score of 3 or more on a 0-10 point scale) at any time during the study.</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="103"/>
                <count group_id="O6" value="90"/>
                <count group_id="O7" value="61"/>
                <count group_id="O8" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="91"/>
                    <measurement group_id="O6" value="74"/>
                    <measurement group_id="O7" value="56"/>
                    <measurement group_id="O8" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Confirmed HZ Episode Related Mortality</title>
        <description>The analysis focused on the number of subjects who died due to HZ</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>GSK1437173A 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>GSK1437173A Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>GSK1437173A Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Placebo 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Placebo 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Confirmed HZ Episode Related Mortality</title>
          <description>The analysis focused on the number of subjects who died due to HZ</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3491"/>
                <count group_id="O2" value="2140"/>
                <count group_id="O3" value="1709"/>
                <count group_id="O4" value="7340"/>
                <count group_id="O5" value="3523"/>
                <count group_id="O6" value="2166"/>
                <count group_id="O7" value="1724"/>
                <count group_id="O8" value="7413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With HZ Related Complications</title>
        <description>The analysis focused on the incidence of HZ complications in subjects with confirmed HZ</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>GSK1437173A 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>GSK1437173A Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>GSK1437173A Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Placebo 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Placebo 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With HZ Related Complications</title>
          <description>The analysis focused on the incidence of HZ complications in subjects with confirmed HZ</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="103"/>
                <count group_id="O6" value="90"/>
                <count group_id="O7" value="61"/>
                <count group_id="O8" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Confirmed HZ Episode Related Hospitalizations</title>
        <description>The analysis focused on confirmed HZ episode related hospitalizations.</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>GSK1437173A 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>GSK1437173A Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>GSK1437173A Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Placebo 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Placebo 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Confirmed HZ Episode Related Hospitalizations</title>
          <description>The analysis focused on confirmed HZ episode related hospitalizations.</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3491"/>
                <count group_id="O2" value="2140"/>
                <count group_id="O3" value="1709"/>
                <count group_id="O4" value="7340"/>
                <count group_id="O5" value="3523"/>
                <count group_id="O6" value="2166"/>
                <count group_id="O7" value="1724"/>
                <count group_id="O8" value="7413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a Confirmed HZ Episode Having a Reduction of Duration of Pain Medication Associated With HZ</title>
        <description>The analysis focused on patients who experienced a reduction in duration of pain medication administered for HZ in subjects with confirmed HZ.</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>GSK1437173A 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>GSK1437173A Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>GSK1437173A Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Placebo 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Placebo 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Confirmed HZ Episode Having a Reduction of Duration of Pain Medication Associated With HZ</title>
          <description>The analysis focused on patients who experienced a reduction in duration of pain medication administered for HZ in subjects with confirmed HZ.</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="103"/>
                <count group_id="O6" value="90"/>
                <count group_id="O7" value="61"/>
                <count group_id="O8" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="82"/>
                    <measurement group_id="O6" value="63"/>
                    <measurement group_id="O7" value="45"/>
                    <measurement group_id="O8" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a Confirmed HZ Episode Taking Pain Medication Associated With HZ</title>
        <description>The analysis focused on subjects taking pain medication due to HZ</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>GSK1437173A 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>GSK1437173A Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>GSK1437173A Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Placebo 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Placebo 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Confirmed HZ Episode Taking Pain Medication Associated With HZ</title>
          <description>The analysis focused on subjects taking pain medication due to HZ</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="103"/>
                <count group_id="O6" value="90"/>
                <count group_id="O7" value="61"/>
                <count group_id="O8" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="82"/>
                    <measurement group_id="O6" value="63"/>
                    <measurement group_id="O7" value="45"/>
                    <measurement group_id="O8" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Severe ‘Worst’ HZ-associated Pain.</title>
        <description>Severe 'worst' pain was defined as HZ-associated pain rated as 3 or above on the 'worst pain' ZBPI questionnaire. This Outcome Measure was only assessed participants with confirmed HZ. This analysis involved any subject reporting ZBPI clinically significant pain (i.e. pain with a score of 3 or more on a 0-10 point scale) at any time during the study.</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>GSK1437173A 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>GSK1437173A Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>GSK1437173A Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Placebo 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Placebo 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Severe ‘Worst’ HZ-associated Pain.</title>
          <description>Severe 'worst' pain was defined as HZ-associated pain rated as 3 or above on the 'worst pain' ZBPI questionnaire. This Outcome Measure was only assessed participants with confirmed HZ. This analysis involved any subject reporting ZBPI clinically significant pain (i.e. pain with a score of 3 or more on a 0-10 point scale) at any time during the study.</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="74"/>
                <count group_id="O7" value="56"/>
                <count group_id="O8" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="11.8"/>
                    <measurement group_id="O2" value="78.0" spread="0.0"/>
                    <measurement group_id="O3" value="9.0" spread="4.2"/>
                    <measurement group_id="O4" value="20.6" spread="26.8"/>
                    <measurement group_id="O5" value="28.7" spread="48.4"/>
                    <measurement group_id="O6" value="21.6" spread="29.3"/>
                    <measurement group_id="O7" value="44.0" spread="74.4"/>
                    <measurement group_id="O8" value="30.2" spread="51.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Confirmed HZ Episode Related Mortality and Hospitalizations</title>
        <description>The analysis focused on confirmed HZ episode related hospitalizations and deaths.</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>GSK1437173A 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>GSK1437173A Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>GSK1437173A Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Placebo 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Placebo 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Confirmed HZ Episode Related Mortality and Hospitalizations</title>
          <description>The analysis focused on confirmed HZ episode related hospitalizations and deaths.</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3491"/>
                <count group_id="O2" value="2140"/>
                <count group_id="O3" value="1709"/>
                <count group_id="O4" value="7340"/>
                <count group_id="O5" value="3523"/>
                <count group_id="O6" value="2166"/>
                <count group_id="O7" value="1724"/>
                <count group_id="O8" value="7413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mortality or hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With HZ Related Complications, by Complication Type</title>
        <description>Complication types included HZ vasculitis, Disseminated Disease, Ophtalmic Disease, Neurologic Disease, Visceral Disease and Stroke. This Outcome Measure was only assessed participants with confirmed HZ.</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>GSK1437173A 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>GSK1437173A Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>GSK1437173A Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Placebo 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Placebo 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With HZ Related Complications, by Complication Type</title>
          <description>Complication types included HZ vasculitis, Disseminated Disease, Ophtalmic Disease, Neurologic Disease, Visceral Disease and Stroke. This Outcome Measure was only assessed participants with confirmed HZ.</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="103"/>
                <count group_id="O6" value="90"/>
                <count group_id="O7" value="61"/>
                <count group_id="O8" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one complication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HZ vasculitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disseminated Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ophtalmic Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurologic Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visceral Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distribution of Pain Medication Associated With HZ</title>
        <description>The distribution of pain medication included 1 to 3 or more separate medications. This Outcome Measure was only assessed participants with confirmed HZ.</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>GSK1437173A 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>GSK1437173A Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>GSK1437173A Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Placebo 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Placebo 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Pain Medication Associated With HZ</title>
          <description>The distribution of pain medication included 1 to 3 or more separate medications. This Outcome Measure was only assessed participants with confirmed HZ.</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="103"/>
                <count group_id="O6" value="90"/>
                <count group_id="O7" value="61"/>
                <count group_id="O8" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one pain medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="82"/>
                    <measurement group_id="O6" value="63"/>
                    <measurement group_id="O7" value="45"/>
                    <measurement group_id="O8" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 pain medication only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 pain medications only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="19"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 pain medications or more</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="22"/>
                    <measurement group_id="O8" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Pain Medication Associated With HZ</title>
        <description>The analysis was performed in subjects with a confirmed HZ episode</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>GSK1437173A 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>GSK1437173A Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>GSK1437173A Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving the GSK1437173A vaccine according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Placebo 50-59 YOA Group</title>
            <description>Subjects aged between 50 and 59 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Placebo 60-69 YOA Group</title>
            <description>Subjects aged between 60 and 69 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Over 70 YOA Group</title>
            <description>Subjects aged above 70 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Overall Ages Group</title>
            <description>Subjects aged over 50 years of age (YOA), receiving placebo according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Pain Medication Associated With HZ</title>
          <description>The analysis was performed in subjects with a confirmed HZ episode</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="82"/>
                <count group_id="O6" value="63"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="14.5"/>
                    <measurement group_id="O2" value="20.5" spread="16.3"/>
                    <measurement group_id="O3" value="63.0" spread="0.0"/>
                    <measurement group_id="O4" value="26.0" spread="21.6"/>
                    <measurement group_id="O5" value="49.2" spread="121.5"/>
                    <measurement group_id="O6" value="74.3" spread="166.3"/>
                    <measurement group_id="O7" value="127.7" spread="266.9"/>
                    <measurement group_id="O8" value="76.1" spread="181.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
        <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.</description>
        <time_frame>During the 7-day (Days 0-6) post-vaccination period</time_frame>
        <population>The analysis was performed on the total vaccinated cohort – Diary Card, which was a subset of subjects from the total vaccinated cohort, who completed diary cards with any solicited symptoms during the 7 days (Day 0 to Day 6) post vaccination period.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A Group</title>
            <description>Subjects received herpes zoster subunit vaccine (gE/AS01B vaccine: GSK1437173A) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
          <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.</description>
          <population>The analysis was performed on the total vaccinated cohort – Diary Card, which was a subset of subjects from the total vaccinated cohort, who completed diary cards with any solicited symptoms during the 7 days (Day 0 to Day 6) post vaccination period.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4379"/>
                <count group_id="O2" value="4375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain, Dose 1 (N=4359,4361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3120"/>
                    <measurement group_id="O2" value="352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 1 (N=4359,4361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 1 (N=4359,4361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1225"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 1 (N=4359,4361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 1 (N=4359,4361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="810"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 1 (N=4359,4361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Dose 2 (N=4207,4224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2807"/>
                    <measurement group_id="O2" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 2 (N=4207,4224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 2 (N=4207,4224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1151"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 2 (N=4207,4224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 2 (N=4207,4224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="762"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 2 (N=4207,4224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Overall (N=4379,4375)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3463"/>
                    <measurement group_id="O2" value="490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Overall (N=4379,4375)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Overall (N=4379,4375)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1665"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Overall (N=4379,4375)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Overall (N=4379,4375)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1153"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Overall (N=4379,4375)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, fever [defined as oral, axillary, rectal or tympanic temperature equal to or above 37.5 degrees Celsius (°C)], headache, myalgia, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
        <time_frame>Within the 7-day (Days 0-6) post-vaccination period</time_frame>
        <population>The analysis was performed on the TVc – Diary Card, which was a subset of subjects from the TVc, who completed diary cards with any solicited symptoms during the 7 days (Day 0 to Day 6) post vaccination period.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A Group</title>
            <description>Subjects received herpes zoster subunit vaccine (gE/AS01B vaccine: GSK1437173A) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
          <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, fever [defined as oral, axillary, rectal or tympanic temperature equal to or above 37.5 degrees Celsius (°C)], headache, myalgia, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was performed on the TVc – Diary Card, which was a subset of subjects from the TVc, who completed diary cards with any solicited symptoms during the 7 days (Day 0 to Day 6) post vaccination period.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4372"/>
                <count group_id="O2" value="4376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Fatigue, Dose 1 (N=4346,4362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1395"/>
                    <measurement group_id="O2" value="531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue, Dose 1 (N=4346,4362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fatigue, Dose 1 (N=4346,4362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1153"/>
                    <measurement group_id="O2" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any GI symptoms, Dose 1 (N=4346,4362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="465"/>
                    <measurement group_id="O2" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 GI symptoms, Dose 1 (N=4346,4362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related GI symptoms, Dose 1 (N=4346,4362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317"/>
                    <measurement group_id="O2" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache, Dose 1 (N=4346,4362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1112"/>
                    <measurement group_id="O2" value="511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache, Dose 1 (N=4346,4362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache, Dose 1 (N=4346,4362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="891"/>
                    <measurement group_id="O2" value="341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia, Dose 1 (N=4346,4362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1446"/>
                    <measurement group_id="O2" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia, Dose 1 (N=4346,4362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia, Dose 1 (N=4346,4362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1231"/>
                    <measurement group_id="O2" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering, Dose 1 (N=4346,4362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="632"/>
                    <measurement group_id="O2" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering, Dose 1 (N=4346,4362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering, Dose 1 (N=4346,4362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="539"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature, Dose 1 (N=4346,4362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="500"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature, Dose 1 (N=4346,4362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature, Dose 1 (N=4346,4362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="420"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue, Dose 2 (N=4205,4222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1456"/>
                    <measurement group_id="O2" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue, Dose 2 (N=4205,4222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fatigue, Dose 2 (N=4205,4222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1270"/>
                    <measurement group_id="O2" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any GI symptoms, Dose 2 (N=4205,4222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="495"/>
                    <measurement group_id="O2" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 GI symptoms, Dose 2 (N=4205,4222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related GI symptoms, Dose 2 (N=4205,4222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache, Dose 2 (N=4205,4222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1249"/>
                    <measurement group_id="O2" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache, Dose 2 (N=4205,4222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache, Dose 2 (N=4205,4222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1107"/>
                    <measurement group_id="O2" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia, Dose 2 (N=4205,4222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1474"/>
                    <measurement group_id="O2" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia, Dose 2 (N=4205,4222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia, Dose 2 (N=4205,4222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1314"/>
                    <measurement group_id="O2" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering, Dose 2 (N=4205,4222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="947"/>
                    <measurement group_id="O2" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering, Dose 2 (N=4205,4222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering, Dose 2 (N=4205,4222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="838"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature, Dose 2 (N=4205,4222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="645"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature, Dose 2 (N=4205,4222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature, Dose 2 (N=4205,4222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="571"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue, Overall (N=4372,4376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2006"/>
                    <measurement group_id="O2" value="728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue, Overall (N=4372,4376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fatigue, Overall (N=4372,4376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1724"/>
                    <measurement group_id="O2" value="522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any GI symptoms, Overall (N=4372,4376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="787"/>
                    <measurement group_id="O2" value="386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 GI symptoms, Overall (N=4372,4376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related GI symptoms, Overall (N=4372,4376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="591"/>
                    <measurement group_id="O2" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache, Overall (N=4372,4376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1714"/>
                    <measurement group_id="O2" value="700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache, Overall (N=4372,4376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache, Overall (N=4372,4376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1470"/>
                    <measurement group_id="O2" value="469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia, Overall (N=4372,4376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2023"/>
                    <measurement group_id="O2" value="529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia, Overall (N=4372,4376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia, Overall (N=4372,4376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1791"/>
                    <measurement group_id="O2" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering, Overall (N=4372,4376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1232"/>
                    <measurement group_id="O2" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering, Overall (N=4372,4376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering, Overall (N=4372,4376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1082"/>
                    <measurement group_id="O2" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature, Overall (N=4372,4376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="940"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature, Overall (N=4372,4376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature, Overall (N=4372,4376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="813"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Grade 3 Symptoms (Solicited and Unsolicited)</title>
        <time_frame>Within the 7-day (Days 0-6) post-vaccination period</time_frame>
        <population>The analysis was performed on the total vaccinated cohort – Diary Card, which was a subset of subjects from the total vaccinated cohort, who completed diary cards with any solicited symptoms during the 7 days (Day 0 to Day 6) post vaccination period.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A Group</title>
            <description>Subjects received herpes zoster subunit vaccine (gE/AS01B vaccine: GSK1437173A) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Grade 3 Symptoms (Solicited and Unsolicited)</title>
          <population>The analysis was performed on the total vaccinated cohort – Diary Card, which was a subset of subjects from the total vaccinated cohort, who completed diary cards with any solicited symptoms during the 7 days (Day 0 to Day 6) post vaccination period.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4457"/>
                <count group_id="O2" value="4464"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited or unsolicited symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3766"/>
                    <measurement group_id="O2" value="1691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 solicited or unsolicited symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="759"/>
                    <measurement group_id="O2" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)</title>
        <description>Occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs) in all subjects</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A Group</title>
            <description>Subjects received herpes zoster subunit vaccine (gE/AS01B vaccine: GSK1437173A) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)</title>
          <description>Occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs) in all subjects</description>
          <population>This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7695"/>
                <count group_id="O2" value="7710"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pIMDs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related pIMDs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With AEs With Any and Related Medically Attended Visit (MAEs)</title>
        <description>Occurrence and relationship to vaccination of medically attended visits (defined as hospitalizations, emergency room visits or visits to or from medical personnel), other than routine health care visits in all subjects.</description>
        <time_frame>From Month 0 to Month 8 post-vaccination</time_frame>
        <population>This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A Group</title>
            <description>Subjects received herpes zoster subunit vaccine (gE/AS01B vaccine: GSK1437173A) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With AEs With Any and Related Medically Attended Visit (MAEs)</title>
          <description>Occurrence and relationship to vaccination of medically attended visits (defined as hospitalizations, emergency room visits or visits to or from medical personnel), other than routine health care visits in all subjects.</description>
          <population>This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7695"/>
                <count group_id="O2" value="7710"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any MAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2952"/>
                    <measurement group_id="O2" value="3072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related MAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
        <description>Occurrence, intensity and relationship to vaccination of unsolicited AEs, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
        <time_frame>Within 30 days (Days 0 - 29) after each vaccination</time_frame>
        <population>This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A Group</title>
            <description>Subjects received herpes zoster subunit vaccine (gE/AS01B vaccine: GSK1437173A) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
          <description>Occurrence, intensity and relationship to vaccination of unsolicited AEs, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
          <population>This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7695"/>
                <count group_id="O2" value="7710"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3534"/>
                    <measurement group_id="O2" value="2426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="609"/>
                    <measurement group_id="O2" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2199"/>
                    <measurement group_id="O2" value="439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>Occurrence and relationship to vaccination of all SAEs in all subjects. Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>Within the 30-day (Days 0-29) post-vaccination period, up to Month 14 and up to study end (3 to 5 year period following Day 0)</time_frame>
        <population>This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1437173A Group</title>
            <description>Subjects received herpes zoster subunit vaccine (gE/AS01B vaccine: GSK1437173A) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>Occurrence and relationship to vaccination of all SAEs in all subjects. Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7695"/>
                <count group_id="O2" value="7710"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAEs (up to Day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs (up to Day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs (up to Month 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="594"/>
                    <measurement group_id="O2" value="590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs (up to Month 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs (up to study end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="727"/>
                    <measurement group_id="O2" value="731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs (up to study end)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited symptoms: within 7 days post-vaccination Unsolicited AEs: within 30 days post vaccination SAEs: during the entire study period (3 to 5 year period following Day 0)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GSK1437173A Group</title>
          <description>Subjects received herpes zoster subunit vaccine (gE/AS01B vaccine: GSK1437173A) according to a 0, 2-month schedule.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Subjects received saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="727" subjects_at_risk="7695"/>
                <counts group_id="E2" subjects_affected="731" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Anaemia vitamin b12 deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Heparin-induced thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Splenic haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="7695"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="7695"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="7695"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="7695"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="7695"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy alcoholic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cardiovascular deconditioning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="7695"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Mitral valve prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="7695"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="7695"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Odontogenic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cystic fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hernia congenital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow’s disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hypopituitarism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Thyroiditis subacute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lens dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Macular cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Neovascular age-related macular degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Crohn’s disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Functional gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gastric mucosal lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gastritis alcoholic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gastrointestinal polyp haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gingival disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Intestinal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Mallory-weiss syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pancreatic fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7695"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Peptic ulcer perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Peritoneal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pneumoperitoneum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Portal hypertensive gastropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Splenic artery aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Thrombosis mesenteric vessel</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="7695"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="7695"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gravitational oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Strangulated hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7695"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7695"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="7695"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Fatty liver alcoholic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Candiduria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="7695"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cellulitis streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cystitis klebsiella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7695"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Encephalomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Fungaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gastroenteritis caliciviral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gastroenteritis clostridial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hepatitis a</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Infected dermal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Leptospirosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lymph node tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Meningitis pneumococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Mycobacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Nasal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Neuroborreliosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="40" subjects_at_risk="7695"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="7695"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Serratia infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Shigella infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Sinusitis fungal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Subdiaphragmatic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Superinfection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Testicular abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Toxic shock syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Tularaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="7695"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Viral sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Visceral leishmaniasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Wound infection pseudomonas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Aneurysm perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cataract operation complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Chemical poisoning</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Electrical burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Eye penetration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7695"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Flail chest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Incarcerated incisional hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Nerve root injury cervical</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Open fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="7695"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Respiratory fume inhalation disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Snake bite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Spinal cord injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Spinal cord injury cervical</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Traumatic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm ruptured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Anticoagulation drug level above therapeutic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Blood heavy metal increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hyperammonaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Joint destruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="7695"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Osteolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Soft tissue mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Still’s disease adult onset</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Abdominal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Acute leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Acute promyelocytic leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Adult t-cell lymphoma/leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Angioimmunoblastic t-cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of orbit</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Benign renal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Benign soft tissue neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bile duct adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bowen’s disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="7695"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bronchial neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the small bowel</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="7695"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Diffuse large b-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Extranodal marginal zone b-cell lymphoma (malt type)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Fallopian tube cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gastrointestinal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Glioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Glomus tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Invasive papillary breast carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Laryngeal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lip and/or oral cavity cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lip squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage i</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="7695"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of pleura metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of unknown primary site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Meningioma benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Metastases to lymph</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Metastases to pleura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Metastatic carcinoma of the bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Nasopharyngeal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Ovarian fibroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7695"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Phaeochromocytoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pleural mesothelioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="7695"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Rectal adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Renal oncocytoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Small intestine adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Spinal cord neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the oral cavity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Testicular neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Vulval cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Basal ganglia haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Basal ganglia infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Carotid artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="7695"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="7695"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Chronic inflammatory demyelinating polyradiculoneuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Dementia alzheimer’s type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Demyelinating polyneuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Guillain-barre syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Haemorrhagic transformation stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Ivth nerve paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Mononeuritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Neuritis cranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Paraneoplastic neurological syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Post polio syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Reversible ischaemic neurological deficit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Ruptured cerebral aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Spinal claudication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="7695"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="7695"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Vasculitis cerebral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Viith nerve paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Delirium febrile</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Generalised anxiety disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Korsakoff’s syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Somatoform disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Renal artery arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Renal artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Urethral polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Endometrial hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Fibrocystic breast disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Uterine enlargement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7695"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="7695"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Paranasal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pickwickian syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pleural calcification</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pulmonary bulla</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7695"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="7695"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Leukoplakia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac pacemaker replacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Angiodysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Aortic dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Aortic rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Arterial disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Bleeding varicose vein</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7695"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Diabetic vascular disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Haemodynamic instability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="7695"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Orthostatic hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Polyarteritis nodosa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Varicose ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7695"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7695"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6046" subjects_at_risk="7695"/>
                <counts group_id="E2" subjects_affected="3313" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="967" subjects_affected="792" subjects_at_risk="7695"/>
                <counts group_id="E2" events="449" subjects_affected="389" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1860" subjects_affected="1464" subjects_at_risk="7695"/>
                <counts group_id="E2" events="314" subjects_affected="276" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3111" subjects_affected="2211" subjects_at_risk="7695"/>
                <counts group_id="E2" events="961" subjects_affected="770" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="636" subjects_affected="493" subjects_at_risk="7695"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="2090" subjects_affected="1390" subjects_at_risk="7695"/>
                <counts group_id="E2" events="118" subjects_affected="104" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="515" subjects_affected="401" subjects_at_risk="7695"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="6064" subjects_affected="3575" subjects_at_risk="7695"/>
                <counts group_id="E2" events="627" subjects_affected="505" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1839" subjects_affected="1498" subjects_at_risk="7695"/>
                <counts group_id="E2" events="176" subjects_affected="168" subjects_at_risk="7710"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="1573" subjects_affected="1154" subjects_at_risk="7695"/>
                <counts group_id="E2" events="48" subjects_affected="46" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3234" subjects_affected="2277" subjects_at_risk="7695"/>
                <counts group_id="E2" events="704" subjects_affected="571" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3044" subjects_affected="2167" subjects_at_risk="7695"/>
                <counts group_id="E2" events="1198" subjects_affected="929" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="2408" subjects_affected="1690" subjects_at_risk="7695"/>
                <counts group_id="E2" events="75" subjects_affected="69" subjects_at_risk="7710"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

